Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Virginia Commonwealth University
With
Novartis Pharmaceuticals
Patients enrolled in the CANTOS trial (with prior acute myocardial infarction \[\>30 days\] and elevated C reactive protein levels \[CRP\>2mg/l\]) who also have reduced left ventricular ejection fraction (LVEF\<50%) and are symptomatic for heart failure (New York Heart Association symptoms class II-III) will be offered to take part in this sub-study at the Virginia Commonwealth University site.
As part of the sub-study, patients will undergo a cardiopulmonary exercise test (CPX) at baseline prior to initiation of treatment, then repeated at 3 and 12 months, and a transthoracic echocardiogram at baseline and at 12 months.
Age
18–110
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
all criteria listed in the CANTOS trial (CACZ885M2301)
left ventricular ejection fraction \<50%
symptoms of heart failure (NYHA class II-III)
You may not be if
all criteria listed in the CANTOS trial (CACZ885M2301)
inability to complete a treadmill exercise test
conditions preventing interpretation of the cardiopulmonary test (arrhythmias, ischemia, hypertension, pulmonary disease)